The short version
EVO Visian ICL is STAAR Surgical’s current-generation Implantable Collamer Lens, in widespread use globally since 2011 and FDA-approved in the US since 2022. The defining feature is a central port — a small opening allowing natural aqueous humor flow through the lens. This eliminates the need for pre-op peripheral iridotomies that older ICL designs required, simplifies the workup, and reduces pupillary block risk. Updated lens material also reduces anterior subcapsular cataract risk. International pricing at ISRS-affiliated clinics runs $3,800-$4,900 per eye.
What EVO ICL is
EVO Visian ICL (Implantable Collamer Lens) is a soft, flexible lens designed for implantation in the posterior chamber of the eye — the space between the iris and the natural crystalline lens. It corrects refractive error (myopia, hyperopia, astigmatism) by adding an optical element inside the eye without altering the cornea or removing the natural lens.
STAAR Surgical, headquartered in Monrovia, California, is the primary global manufacturer of ICL. Their product line has evolved through several generations:
- Visian ICL V4 (1997): First-generation FDA-approved ICL in various international markets. Required peripheral iridotomies pre-op.
- Visian ICL V4c (2011): First ICL design with central port. Introduced internationally in 2011.
- EVO Visian ICL / EVO+ (current): Refined central-port design with updated material characteristics. FDA-approved in the US in 2022.
At credentialed refractive centers worldwide as of 2026, EVO ICL is essentially the standard of care for new ICL implants. Older-generation ICL designs are being phased out.
The central port: what it does
The defining feature of EVO ICL is a small central port — a hole approximately 360 microns in diameter at the center of the lens. This port allows natural aqueous humor (the fluid inside the front of the eye) to flow between the anterior chamber (in front of the iris) and the posterior chamber (behind the iris where the ICL sits).
Why aqueous flow matters
Aqueous humor is produced by the ciliary body behind the iris and flows through the pupil into the anterior chamber, where it drains through the trabecular meshwork at the angle. This flow maintains intraocular pressure and delivers nutrients to the cornea and lens.
Older ICL designs sat behind the iris and blocked this flow, requiring aqueous to circulate around the outer edge of the lens. When lens sizing was even slightly imperfect (too little clearance between the lens edge and the iris), aqueous flow could be restricted — a condition called pupillary block that can cause acute glaucoma with rapid IOP elevation.
The solution with older ICL: surgeons created two peripheral iridotomies (small openings in the iris) with a YAG laser 1-2 weeks before ICL surgery. These openings provided alternative pathways for aqueous flow around the lens.
The EVO central port solves the same problem more elegantly. Aqueous flows through the port at the center of the lens regardless of edge clearance. Iridotomies are no longer needed. Pupillary block risk is essentially eliminated.
Practical implications for patients
- Simplified pre-op process: No separate iridotomy appointment 1-2 weeks before ICL surgery.
- Lower complication risk: Reduced risk of pupillary block glaucoma.
- Easier post-op monitoring: Fewer variables to check at follow-up visits.
- Better patient experience: One fewer procedure to schedule, one fewer recovery period to account for.
Cost across five destinations
EVO Visian ICL per-eye pricing, 2026
Midpoint of published clinic ranges in USD. Includes surgical fee and EVO lens cost. Toric EVO ICL for astigmatism adds $200-$400 per eye.
All figures per eye, USD, typical 2026 ranges from published clinic pricing. Not quotes.
For bilateral EVO ICL at Colombia or Turkey pricing, budget $7,600-$8,200 total surgical cost. US pricing runs $15,000-$18,000. Since EVO eliminates the pre-op iridotomy step, patients save both the cost of that separate procedure ($200-$600 in the US) and the extra clinic visits.
How EVO differs from older ICL designs
Central port (main difference)
Covered above. The central port is the defining feature that distinguishes EVO from earlier ICL generations.
Updated lens material
EVO uses a refined version of the collamer material with improved biocompatibility characteristics. The material shows reduced tendency toward anterior subcapsular cataract formation compared to older designs. This is meaningful because anterior subcapsular cataract at the natural lens surface was a known small risk with older ICL designs, particularly in cases with low vault (insufficient distance between the ICL and the natural lens).
Refined lens footplates
The footplates (the parts of the lens that rest in the ciliary sulcus and stabilize positioning) have been refined in the EVO design for improved stability and reduced rotation risk. This is particularly relevant for Toric ICL where lens rotation directly affects astigmatism correction outcomes.
Expanded size range
The EVO product line includes a broader range of lens sizes than earlier generations, allowing better fit for the full range of anterior segment anatomies encountered in the global patient population. Standard sizes: 12.1, 12.6, 13.2, 13.7mm; extended sizes available for special cases.
Regulatory approval trajectory
EVO was FDA-approved in the US in March 2022 based on multi-center clinical trial data. It had been in widespread international use since 2011, so US surgeons had access to a decade of international outcomes data during their initial adoption. Adoption at US refractive centers has been rapid; most refractive centers now offer EVO as their standard ICL option.
Destination comparison for EVO ICL candidates
Destination factors specific to EVO ICL: case volume with the current-generation lens, anterior segment OCT depth (for vault monitoring), STAAR ICL sizing expertise, and follow-up depth. Some clinics have transitioned fully to EVO; others still use older ICL designs alongside — ask specifically what your clinic will implant.
Five destinations rated for EVO ICL candidates
Higher = better fit. Editorial scoring based on EVO adoption, anterior segment OCT infrastructure, and case volume.
Scored 1–10 by our editorial team based on public clinic data, patient reports, and on-the-ground network experience. Not medical advice.
Colombia profiles very strongly for EVO ICL. Hospital-affiliated Bogotá and Medellín centers have transitioned fully to EVO for new implants. STAAR ICL sizing expertise is deep — the ISRS-affiliated centers have long-standing partnerships with STAAR training and support. Anterior segment OCT for vault monitoring is standard at credentialed centers.
Turkey has arguably the deepest EVO ICL adoption globally, with case volumes at Istanbul centers matching the highest-volume US and European practices. STAAR ICL platform breadth is excellent.
Mexico has strong EVO programs at Mexico City and Guadalajara centers. Sizing expertise is good; anterior segment OCT availability is variable.
Thailand has strong EVO adoption. Better fit for patients based in Asia or the Pacific.
Costa Rica offers convenient proximity for US East Coast patients; EVO case volume is lower than at top-tier destinations.
The EVO ICL surgery step by step
- Pre-op preparation: Standard anti-inflammatory drops for 24-48 hours pre-op. No iridotomies required.
- Anesthesia: Topical anesthetic drops. Some clinics also use mild oral sedation for patient comfort.
- Corneal incision: A small (2.8-3.2mm) clear corneal incision is made, typically at the temporal or superior corneal periphery.
- Viscoelastic instillation: Cohesive viscoelastic is injected into the anterior chamber to protect corneal endothelium and maintain chamber depth.
- Lens insertion: The EVO ICL is loaded into an injector cartridge and inserted through the incision. The lens unfolds slowly in the anterior chamber.
- Lens positioning: The surgeon carefully positions the lens footplates into the ciliary sulcus behind the iris, ensuring proper centration.
- Viscoelastic removal: Irrigation and aspiration removes the viscoelastic material.
- Incision closure: The corneal incision typically self-seals without sutures.
- Post-op protocol: Antibiotic and steroid drops for 1-2 weeks. IOP check at 4-6 hours post-op and next-day follow-up.
Total procedure time per eye: typically 15-20 minutes. Most patients are back to their hotel or accommodation within an hour of the procedure.
Post-op monitoring specific to EVO
Vault monitoring via anterior segment OCT
Vault (distance between the ICL and the natural lens) is measured at post-op visits via anterior segment OCT. Ideal vault is 250-750 microns. Vault outside this range may prompt intervention:
- Low vault (below 150 microns): Risk of contact with natural lens, anterior subcapsular cataract. May require lens exchange for larger size.
- High vault (above 900 microns): Risk of pigment dispersion, IOP elevation, iris chafing. May require lens exchange for smaller size.
The central port design of EVO makes vault less critical for aqueous flow (older designs required specific vault to maintain flow around the lens edge). Vault remains important for anatomical fit but is not a safety-critical measurement in the same way it was for older designs.
Endothelial cell count monitoring
Baseline specular microscopy documents corneal endothelial health pre-op. Follow-up at year 1, 3, 5, and beyond confirms endothelial cell density remains adequate. Age-related decline is expected (~0.5-1% per year); ICL-related additional loss should be minimal in well-executed cases.
IOP monitoring
Intraocular pressure checks at 4-6 hours post-op, next-day, week 1, month 1, and every 3-6 months for the first year. The central port in EVO essentially eliminates acute pupillary block, but ongoing IOP surveillance remains standard.
EVO ICL consultation and planning
We coordinate EVO Visian ICL consultations at ISRS-affiliated hospital-adjacent clinics across Colombia, Turkey, and Mexico with strong EVO case volume. Comprehensive anterior segment workup, current-generation lens selection, and long-term surveillance planning. Same-timezone WhatsApp from our Medellín office.
Frequently asked questions
What is EVO ICL?
EVO Visian ICL is STAAR Surgical’s current-generation Implantable Collamer Lens. The defining feature is a central port — a small hole in the center of the lens that allows natural aqueous humor to flow through the lens. This eliminates the need for the peripheral iridotomies that older ICL designs required, simplifies the pre-op process, and reduces the risk of pupillary block glaucoma. EVO received FDA approval in the US in 2022.
How is EVO different from older ICL?
Three main differences. First, the central port eliminates the need for pre-op YAG iridotomies. Second, the material has been updated for improved biocompatibility and reduced anterior subcapsular cataract risk. Third, the FDA approval process (2022 in the US) reflected updated safety and efficacy data. EVO is essentially the standard of care for new ICL implants at credentialed centers worldwide as of 2026.
Are pre-op iridotomies still needed with EVO?
No. The central port in EVO ICL maintains aqueous humor flow between the anterior and posterior chambers, eliminating the pupillary block mechanism that older ICL designs required iridotomies to address. This simplifies the pre-op process (older ICL required patients to schedule YAG laser iridotomies 1-2 weeks before ICL surgery) and reduces overall procedure complexity.
What is the central port and why does it matter?
The central port is a small opening (typically 360 microns diameter) in the center of the EVO lens. It allows natural aqueous humor to flow through the lens, maintaining normal fluid dynamics between the anterior chamber (in front of the iris) and posterior chamber (behind the iris where the ICL sits). This flow is essential for maintaining normal intraocular pressure. Older ICL designs blocked this flow, requiring surgeon-created iridotomies to allow flow around the lens edge.
Does the central port affect vision?
The central port is designed to be optically transparent at typical pupil sizes and doesn’t create meaningful vision effects for most patients. In very low light conditions when the pupil dilates significantly, a small minority of patients report slight visual artifacts around lights. The clinical impact is generally minimal and typically resolves through neuroadaptation over the first few months.
Is EVO ICL more expensive than older ICL?
Slightly. EVO typically prices $200-$400 higher per eye than older-design ICL. The difference reflects the newer technology and the simplified pre-op process (eliminating separate iridotomy procedures). Most patients find the elimination of iridotomies and the simplified overall process worth the modest cost premium. Older ICL designs are being phased out at most credentialed centers as EVO becomes the standard.
What are the long-term outcomes for EVO ICL?
Published outcomes at 5-10 years show excellent refractive stability, low complication rates, and preserved endothelial cell counts within expected age-related decline. The updated material shows reduced anterior subcapsular cataract rates compared to older ICL designs. Extended surveillance continues; the design has been in widespread use since 2011 internationally and since 2022 in the US.